<DOC>
	<DOCNO>NCT00422786</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy CAP-232 treatment patient previously treat ( refractory ) renal cell carcinoma</brief_summary>
	<brief_title>Phase II Study CAP-232 Patients With Refractory Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This multi-center , open label , single arm study . Approximately 40 patient initially plan recruit . Each patient receive treatment cycle consist CAP-232 via continuous IV infusion 21 day 0.48 mg/kg/day follow 7-day rest period . Treatment cycle repeat absence disease progression unacceptable toxicity . Quality Life questionnaire administer baseline , visit end study . Signs symptoms adverse event closely monitor treatment cycle . Safety laboratory measure do Screening , 72hr hospitalization ( first cycle ) , every interim visit , end study . A follow-up safety visit schedule least 30 day end treatment . CAP-232 plasma level also determine .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Histologically confirm stage IV kidney clear cell carcinoma . Confirmed progressive disease receive previous systemic therapy , include least one line standard care . Measurable disease Age &gt; 18 year . Life expectancy great 3 month . At least 5 year free cancer ( ) . Basal cell carcinoma , provide neither infiltrate sclerosing carcinoma situ cervix , acceptable . ECOG performance status 2 low ( Karnofsky 60 % ) . Normal organ marrow function Adequate contraception prior study entry duration study participation . Ability understand willingness sign write informed consent document . Ability receive central vein access catheter manage infusion pump . Women child bear potential must negative serum pregnancy test . Anticancer therapy within 4 week prior enter study Investigational agent less 30 day prior enrollment study . Known brain metastasis History allergic reaction attribute compound similar composition CAP232 . Past current cancer kidney cancer , except : Curatively treat nonmelanoma skin cancer , In situ carcinoma cervix , Other cancer curatively treat evidence disease least 5 year Uncontrolled intercurrent illness /social situation would limit compliance study requirement . Breastfeeding Patients previously enrol study subsequently withdraw</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Refractory Clear Cell Renal Cell Carcinoma</keyword>
	<keyword>Phase II</keyword>
	<keyword>Thallion</keyword>
	<keyword>TLN-232</keyword>
	<keyword>CAP-232</keyword>
	<keyword>M2PK</keyword>
</DOC>